Hanfang Jiang

957 total citations
65 papers, 659 citations indexed

About

Hanfang Jiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hanfang Jiang has authored 65 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 24 papers in Cancer Research. Recurrent topics in Hanfang Jiang's work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (13 papers). Hanfang Jiang is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (13 papers). Hanfang Jiang collaborates with scholars based in China, Ethiopia and United States. Hanfang Jiang's co-authors include Huiping Li, Guohong Song, Hope S. Rugo, Lijun Di, Ying Yan, Heping Wang, Yuejie Zheng, Ping Liu, Jikui Deng and Wenjian Wang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Virology.

In The Last Decade

Hanfang Jiang

57 papers receiving 654 citations

Peers

Hanfang Jiang
Simona Scalone Italy
Yuwen Zhou China
Andrea Beer Austria
Georgios Polychronidis Germany
Alexandra Thomas United States
Anna Diana Italy
Xuemin Chen China
J. Palou-Redorta Spain
Rutie Yin China
Simona Scalone Italy
Hanfang Jiang
Citations per year, relative to Hanfang Jiang Hanfang Jiang (= 1×) peers Simona Scalone

Countries citing papers authored by Hanfang Jiang

Since Specialization
Citations

This map shows the geographic impact of Hanfang Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanfang Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanfang Jiang more than expected).

Fields of papers citing papers by Hanfang Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanfang Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanfang Jiang. The network helps show where Hanfang Jiang may publish in the future.

Co-authorship network of co-authors of Hanfang Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Hanfang Jiang. A scholar is included among the top collaborators of Hanfang Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanfang Jiang. Hanfang Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ullah, Zia, Hanfang Jiang, Yushan Yan, et al.. (2026). Unraveling the Hidden Balance between Quantum Confinement and Structural Modifications in Near-Infrared Fluorescent Carbon Dots. Chemical & Biomedical Imaging.
2.
3.
Wang, Nan, Xiaoran Liu, Ying Yan, et al.. (2024). HER2 status results in an unstable switch from primary to recurrent breast cancer. Neoplasma. 71(4). 392–401. 1 indexed citations
4.
Jiang, Hanfang, et al.. (2024). Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer. Breast Cancer Research and Treatment. 204(3). 617–629. 4 indexed citations
5.
Jiang, Hanfang, Huiping Li, Guohong Song, et al.. (2023). Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Research and Treatment. 199(1). 67–79. 5 indexed citations
6.
Jiang, Hanfang, Fei Ma, Jiayu Wang, et al.. (2023). Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China. Thoracic Cancer. 14(34). 3397–3405. 1 indexed citations
7.
Zhang, Ruyan, Yifei Chen, Xiaoran Liu, et al.. (2023). Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting. Frontiers in Oncology. 13. 1076469–1076469. 2 indexed citations
8.
Shao, Bin, Huiping Li, Xiaoran Liu, et al.. (2023). The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. Annals of Translational Medicine. 11(2). 45–45. 7 indexed citations
9.
Jiang, Hanfang & Huiping Li. (2021). Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 21(1). 149–149. 154 indexed citations
10.
Zhang, Ruyan, Xiaoran Liu, Bin Shao, et al.. (2021). Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study. Asia-Pacific Journal of Clinical Oncology. 17(4). 396–402. 9 indexed citations
11.
Li, Huiping, Guohong Song, Ran Ran, et al.. (2021). Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. Breast Cancer Research and Treatment. 189(3). 725–736. 5 indexed citations
12.
Jiang, Hanfang, Ruyan Zhang, Xiaoran Liu, et al.. (2021). Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016). Cancer Medicine. 10(17). 6089–6098. 6 indexed citations
13.
Yi, Yan, Hanfang Jiang, Ling Xu, et al.. (2020). [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].. PubMed. 52(2). 254–260. 7 indexed citations
14.
Liu, Xiaoran, Jianjun Yu, Guohong Song, et al.. (2020). Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. The Breast. 55. 7–15. 4 indexed citations
15.
Lei, Wen, Huiping Li, Guohong Song, et al.. (2020). Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. Journal of Cancer. 11(22). 6612–6622. 8 indexed citations
16.
17.
Liu, Xiaorong, et al.. (2017). Exploration of high-throughput sequencing method in severe pneumonia pathogens detection. Zhonghua jianyan yixue zazhi. 40(8). 609–613. 2 indexed citations
18.
Liang, Xu, Jie Zhang, Xinna Zhou, et al.. (2012). Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clinical & Translational Oncology. 15(4). 331–334. 18 indexed citations
19.
Ma, Bo, Hanfang Jiang, Jun Jia, et al.. (2012). Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clinical & Translational Oncology. 14(10). 764–773. 25 indexed citations
20.
Ren, Jun, Jun Jia, Hongmei Zhang, et al.. (2008). Dendritic cells pulsed with α‐fetoprotein and mutant P53 fused gene induce bi‐targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Science. 99(7). 1420–1426. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Scalone Breakdown of academic impact, for papers by Yuwen Zhou Breakdown of academic impact, for papers by Andrea Beer Breakdown of academic impact, for papers by Georgios Polychronidis Breakdown of academic impact, for papers by Alexandra Thomas Breakdown of academic impact, for papers by Anna Diana Breakdown of academic impact, for papers by Xuemin Chen Breakdown of academic impact, for papers by J. Palou-Redorta Breakdown of academic impact, for papers by Rutie Yin
Rankless by CCL
2026